Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Bayer's ear to the ground

    Why Bayer is investing up to $25M in Versant's fifth fund

    Ebb & Flow Bayer's ear to the ground The Bayer HealthCare unit of Bayer AG (Xetra:BAYN) is expanding its relationship with Versant Ventures by becoming an LP in the VC firm's new fund. Christopher Haskell, head of …

    Published on 11/10/2014
  • Convert resurgence

    Why biotech convertible debt deals are at highest levels since 2006

    Ebb & Flow Convert resurgence Figure: Money Raised in 2014 Figure: Converting the middle Table: Earnings on deck Table: EPS watch Biotechs have raised $5.6 billion through convertible debt financings so far this…

    Published on 11/10/2014
  • Fresh fund, same plan

    Advent sticking with investment strategy for L145.5M second life sciences fund

    Ebb & Flow Fresh fund, same plan Advent Venture Partners plans to stick with its long-standing investment strategy for its second dedicated life sciences fund, Advent Life Sciences Fund II, which the firm closed …

    Published on 11/3/2014
  • Figure: Money Raised in 2014

    Shooting F-stars Money Raised in 2014 Last week, the biotech industry raised $630 million, bringing to $43.8 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 11/3/2014
  • Table: Earnings on deck

    Shooting F-stars Earnings on deck At least 17 biotechs and pharmas are slated to report earnings this week. Two large-cap biotechs - Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Salix Pharmaceuticals Ltd. (…

    Published on 11/3/2014
  • Table: EPS watch

    Shooting F-stars EPS watch At least 34 biotechs and pharmas reported earnings last week. Amgen Inc. (NASDAQ:AMGN) tacked on $11.4 billion in market cap value after beating the Street's EPS and revenue estimates and …

    Published on 11/3/2014
  • Shooting F-stars

    How BMS deal validates F-star's asset-centric spinout strategy

    Ebb & Flow Shooting F-stars Figure: Money Raised in 2014 Table: Earnings on deck Table: EPS watch F-star Alpha Ltd.'s deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent …

    Published on 11/3/2014
  • Enhancing super-enhancers

    Syros to use $53M to advance cancer program, expand super-enhancer platform

    Ebb & Flow Enhancing super-enhancers With a new injection of cash, Syros Pharmaceuticals Inc. plans to move its lead cancer program into the clinic, continue to build out its super-enhancer platform technology and …

    Published on 11/3/2014
  • Metallic strategy

    Why Viamet chose to stay private and spin out cancer assets

    Ebb & Flow Metallic strategy Viamet Pharmaceuticals Inc.'s decision to do a $60 million series D round one day after withdrawing its planned $75 million IPO late last month can be explained by a "choppy" IPO market …

    Published on 11/3/2014
  • Not slowing down

    Biogen Idec says $100M cut doesn't mean less BD

    Ebb & Flow Not slowing down The $100 million reduction by Biogen Idec Inc. (NASDAQ:BIIB) of guidance for business development spending for the remainder of the year does not reflect a change in strategy or appetite,…

    Published on 10/27/2014
  • Tecfidera tremors

    Buysiders say jittery investors overreacted on Biogen's Tecfidera sales, PML case

    Ebb & Flow Tecfidera tremors Buysiders said investors overreacted when they shaved as much as $8.5 billion off the market cap of Biogen Idec Inc. (NASDAQ:BIIB) on Wednesday on 3Q14 sales of Tecfidera dimethyl …

    Published on 10/27/2014
  • Figure: Money Raised in 2014

    Waiting for better times Money Raised in 2014 Last week, the biotech industry raised $431 million, bringing to $43.1 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14…

    Published on 10/27/2014
  • Table: Earnings on deck

    Waiting for better times Earnings on deck At least 31 biotechs and pharmas are slated to report earnings this week. Investors will be closely watching Amgen Inc. (NASDAQ:AMGN) when it reports earnings on Monday for …

    Published on 10/27/2014
  • Table: EPS watch

    Waiting for better times EPS watch At least 18 biotechs and pharmas reported earnings last week. Four large-cap biotechs - Actelion Ltd. (SIX:ATLN), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), BioMarin …

    Published on 10/27/2014
  • Figure: NewLink on the move

    Playing NewLink NewLink on the move Shares of NewLink Genetics Corp. (NASDAQ:NLNK) since April 30.

    Published on 10/27/2014
  • Waiting for better times

    Why Molecular Partners postponed the fourth-largest EU biotech IPO since 2008

    Ebb & Flow Waiting for better times Figure: Money Raised in 2014 Table: Earnings on deck Table: EPS watch Poised to complete the fourth-largest European biotech IPO since 2008, the road show for Molecular …

    Published on 10/27/2014
  • Playing NewLink

    Why NewLink's $150 million Genentech deal only added $58 million in market cap

    Ebb & Flow Playing NewLink Figure: NewLink on the move Profit-taking on a 60% run-up earlier in October could explain why shares of NewLink Genetics Corp. (NASDAQ:NLNK) added only $58.4 million in market cap on Oct…

    Published on 10/27/2014
  • Bicycle pedals on

    Bicycle to use £20M to move two bicycle-drug conjugates into clinic for cancer

    Ebb & Flow Bicycle pedals on Bicycle Therapeutics Ltd. plans to use a new cash injection to develop its pipeline of bicycle-drug conjugates (BDCs), with the goal of having its first candidate in the clinic for solid…

    Published on 10/20/2014
  • Figure: Money Raised in 2014

    Sticking with big Money Raised in 2014 Last week, the biotech industry raised $710 million, bringing to $42.7 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 10/20/2014
  • Table: Earnings on deck

    Sticking with big Earnings on deck At least 13 biotechs and pharmas are slated to report earnings this week. Two large-cap biotechs - Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Biogen Idec Inc. (NASDAQ:BIIB) - …

    Published on 10/20/2014
  • Table: EPS watch

    Sticking with big EPS watch At least three companies reported earnings last week. Shares of Baxter International Inc. (NYSE:BAX) and Johnson & Johnson (NYSE:JNJ) were off more than 2% despite beating consensus EPS …

    Published on 10/20/2014
  • Raising for Raze

    How Atlas built Raze to explore novel mitochondrial metabolism targets in cancer

    Ebb & Flow Raising for Raze Atlas Venture built platform company Raze Therapeutics Inc. to explore multiple targets and pathways associated with mitochondrial one-carbon metabolism, which the company thinks will …

    Published on 10/20/2014
  • Sticking with big

    Why Canaan is sticking with hybrid venture model for $675M tenth fund

    Ebb & Flow Sticking with big Figure: Money Raised in 2014 Table: Earnings on deck Table: EPS watch At a time when many venture firms have been raising smaller funds, Canaan Partners closed its tenth at $675 …

    Published on 10/20/2014
  • Figure: Money Raised in 2014

    Venture's banner year Money Raised in 2014 Last week, the biotech industry raised $338 million, bringing to $41.9 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 10/13/2014
  • Table: Earnings on Deck

    Venture's banner year Earnings on deck Earnings season kicks off this week with at least three companies slated to report financial results. 3Q14 EPS for Baxter International Inc. (NYSE:BAX) is expected to jump 10% …

    Published on 10/13/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993